Sapu Bioscience

Sapu Bioscience is an immuno-oncology company dedicated to developing first-class RNA therapies and small molecule drugs for cancer and infectious diseases. OT-101, the leading immuno-oncology candidate of Sapu Bioscience, is a first-of-its-kind anti-TGF-β RNA therapy that has demonstrated single-agent activity in clinical trials for patients with relapsed/refractory cancers. OT-101 also exhibits activity against SARS-CoV-2. Sapu Bioscience is seeking to leverage its deep expertise in drug development to improve treatment outcomes and survival rates for cancer patients, with a particular focus on rare pediatric cancers. Sapu Bioscience holds the rare pediatric designation for DIPG (OT-101).